⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL27419867 | 0.78 | — | — | |
| SCHEMBL1680597 | 0.76 | — | — | |
| SCHEMBL11153371 | 0.76 | — | — | |
| SCHEMBL31234346 | 0.76 | — | — | |
| SCHEMBL5014124 | 0.76 | — | — | |
| SCHEMBL9834069 | 0.76 | — | — | |
| SCHEMBL2645752 | 0.76 | — | — | |
| SCHEMBL2649622 | 0.76 | — | — | |
| SCHEMBL7992764 | 0.76 | — | — | |
| SCHEMBL16381970 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171545-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | VALO HEALTH, INC. | 2021-06-10 | — | — | US | claimed |
| US-9822129-B2 | Amido spirocyclic amide and sulfonamide derivatives | GENENTECH, INC. (US) | 2017-11-21 | — | — | US | claimed |
| US-20170216262-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | VALO EARLY DISCOVERY, INC. | 2017-08-03 | — | — | US | claimed |
| EP-2820008-B1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | GENENTECH INC (US) | 2016-12-14 | — | — | EP | claimed |
| US-20160002266-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | claimed |
| CN-104520290-A | Amido spirocyclic amide and sulfonamide derivatives | GENENTECH INC | 2015-04-15 | — | — | CN | claimed |
| US-8586550-B2 | Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2013-11-19 | — | — | US | claimed |
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | claimed |
| WO-2011159067-A2 | THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2011-12-22 | — | — | WO | claimed |
| US-7226926-B2 | 8-fluoroimidazo 1,2-a pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2007-06-05 | — | — | US | claimed |
| US-20210171545-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | VALO HEALTH, INC. | 2021-06-10 | — | — | US | disclosed |
| CN-104520290-B | Amido spirocyclic amide and sulfonamide derivatives | 基因科技股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| US-10730889-B2 | Amido spirocyclic amide and sulfonamide derivatives | FORMA TM, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20180339998-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | Valo Health, LLC | 2018-11-29 | — | — | US | disclosed |
| US-9822129-B2 | Amido spirocyclic amide and sulfonamide derivatives | GENENTECH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| WO-2003086406-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003053444-A1 | NEW USE | ASTRAZENECA AB (SE) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003048132-A1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002076983-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-03 | — | — | WO | disclosed |